HIGH POINT, N.C.--(BUSINESS WIRE)--TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease. The...
Featured News & Resources Descartes Solution Streamlines Air Shipment Data Exchange with IATA’s ONE Record Read the PRESS RELEASEabout Descartes Solution Streamlines Air Shipment Data Exchange with IATA’s ONE Record Austrian Airlines Is Managing Inventory & Optimizing Processes Using Descartes RFID Tech...